FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3023367083> ?p ?o ?g. }

• W3023367083 endingPage "1372" @default.
• W3023367083 startingPage "1372" @default.
• W3023367083 abstract "Conclusion: Performance of percutaneous angioplasty of the superficial femoral artery (SFA) using Paclitaxel-coated angioplasty balloons results in significant reductions in late lumen loss and target lesion revascularization. Summary: A previous trial of a sirolimus-coated stents for SFA angioplasty failed to reveal benefit when compared to un-coated stents (Circ 2002;106:1505-9). There have, however, been animal trials that the use of Paclitaxel as a coating on angioplasty balloons and also when added to contrast media, can reduce vascular smooth muscle cell proliferation and therefore decrease intimal hyperplasia. In this study the authors investigated the use of Paclitaxel-coated angioplasty balloons and the addition of Paclitaxel to contrast media on lower extremitiy angioplasty. This trial randomly assigned 154 patients with stenosis or occlusion of the femoral/popliteal artery to treatment with standard balloon catheters coated with Paclitaxel, treatment with uncoated balloons but with Paclitaxel dissolved in the contrast medium, or to treatment with uncoated balloons without Paclitaxel in the contrast medium (control group). Three centers in Germany participated in the study. The study was sponsored by Bavaria Medizintecnologie and Schering, Germany. The primary end point was lumen loss at six months. Mean age of the patients was 68 ± 8 years. Forty nine percent of the patients had diabetes. Of the lesions treated, 27% were total occlusions and 36% were restenotic lesions. Mean lesion length was 7.4 ± 6.5 cm. The study groups had no significant demographic differences. All patients received 75 mg of Clopidogril daily for four weeks after intervention, and 100 mg of aspirin daily indefinitely. Plasma Paclitaxel concentrations were determined immediately and two hours after intervention, using high performance liquid choromatography. Residual Paclitaxel on the balloon after use was also determined. Fifty four patients were assigned to the control group, 48 to treatment with Paclitaxel-coated balloons, and 52 to treatment with Paclitaxel in the contrast medium. Mean ankle-brachial index prior to intervention was 0.5 ± 0.3. Late lumen loss was determined by angiography and 83% of the patients underwent angiography at six months of follow-up. At six months, mean late lumen loss in the control group was 1.7 ± 1.8 mm. In the group treated with Paclitaxel-coated balloons it was 0.4 ± 1.2 mm (P < 0.001). In the group treated with Paclitaxel only in the contrast medium mean late lumen loss at six months was 2.2 ± 1.6 mm (P = 0.11 compared to the control group). Revascularization of target lesions at six months was 37% in the control group, 4% in the group treated with Paclitaxel-coated balloons (P < 0.001), and 29% in the group treated with Paclitaxel only in the contrast medium (P = 0.41). At 24 months, revascularization rates increased to 52% in the control group, 15% in the group treated with Paclitaxel-coated balloons, and 40% in the group treated with Paclitaxel in the contrast medium. Maximum plasma Paclitaxel concentration remained below detectable limits in 40 of 42 patients treated with coated balloons. The majority of patients with Paclitaxel in the contrast medium had measurable plasma concentrations immediately after the procedure. Comment: The results of this study seem almost too good to be believed. Nevertheless, based on the animal data, they are not inconceivable. The investigators, however, were not fully blinded to the treatment arm of the individual patients. Some also served as consultants and received grant support from the industry sponsors or are involved in patent applications with respect to the techniques used in the trial. Fully blinded studies with non-potentially biased investigators will be required." @default.
• W3023367083 created "2020-05-13" @default.
• W3023367083 creator A5023019539 @default.
• W3023367083 creator A5069076517 @default.
• W3023367083 creator A5076600562 @default.
• W3023367083 date "2008-06-01" @default.
• W3023367083 modified "2023-09-30" @default.
• W3023367083 title "Local Delivery of Paclitaxel to Inhibit Re-Stenosis During Angioplasty of the Leg" @default.
• W3023367083 doi "https://doi.org/10.1016/j.jvs.2008.04.039" @default.
• W3023367083 hasPublicationYear "2008" @default.
• W3023367083 type Work @default.
• W3023367083 sameAs 3023367083 @default.
• W3023367083 citedByCount "1" @default.
• W3023367083 countsByYear W30233670832017 @default.
• W3023367083 crossrefType "journal-article" @default.
• W3023367083 hasAuthorship W3023367083A5023019539 @default.
• W3023367083 hasAuthorship W3023367083A5069076517 @default.
• W3023367083 hasAuthorship W3023367083A5076600562 @default.
• W3023367083 hasBestOaLocation W30233670831 @default.
• W3023367083 hasConcept C126322002 @default.
• W3023367083 hasConcept C126838900 @default.
• W3023367083 hasConcept C126894567 @default.
• W3023367083 hasConcept C131631996 @default.
• W3023367083 hasConcept C139059822 @default.
• W3023367083 hasConcept C141071460 @default.
• W3023367083 hasConcept C2776268601 @default.
• W3023367083 hasConcept C2776694085 @default.
• W3023367083 hasConcept C2777292972 @default.
• W3023367083 hasConcept C2777303625 @default.
• W3023367083 hasConcept C2778283817 @default.
• W3023367083 hasConcept C2778583881 @default.
• W3023367083 hasConcept C2779464278 @default.
• W3023367083 hasConcept C2779723990 @default.
• W3023367083 hasConcept C2780007028 @default.
• W3023367083 hasConcept C2780326628 @default.
• W3023367083 hasConcept C2781156865 @default.
• W3023367083 hasConcept C500558357 @default.
• W3023367083 hasConcept C71924100 @default.
• W3023367083 hasConceptScore W3023367083C126322002 @default.
• W3023367083 hasConceptScore W3023367083C126838900 @default.
• W3023367083 hasConceptScore W3023367083C126894567 @default.
• W3023367083 hasConceptScore W3023367083C131631996 @default.
• W3023367083 hasConceptScore W3023367083C139059822 @default.
• W3023367083 hasConceptScore W3023367083C141071460 @default.
• W3023367083 hasConceptScore W3023367083C2776268601 @default.
• W3023367083 hasConceptScore W3023367083C2776694085 @default.
• W3023367083 hasConceptScore W3023367083C2777292972 @default.
• W3023367083 hasConceptScore W3023367083C2777303625 @default.
• W3023367083 hasConceptScore W3023367083C2778283817 @default.
• W3023367083 hasConceptScore W3023367083C2778583881 @default.
• W3023367083 hasConceptScore W3023367083C2779464278 @default.
• W3023367083 hasConceptScore W3023367083C2779723990 @default.
• W3023367083 hasConceptScore W3023367083C2780007028 @default.
• W3023367083 hasConceptScore W3023367083C2780326628 @default.
• W3023367083 hasConceptScore W3023367083C2781156865 @default.
• W3023367083 hasConceptScore W3023367083C500558357 @default.
• W3023367083 hasConceptScore W3023367083C71924100 @default.
• W3023367083 hasIssue "6" @default.
• W3023367083 hasLocation W30233670831 @default.
• W3023367083 hasOpenAccess W3023367083 @default.
• W3023367083 hasPrimaryLocation W30233670831 @default.
• W3023367083 hasRelatedWork W1906079458 @default.
• W3023367083 hasRelatedWork W2004142456 @default.
• W3023367083 hasRelatedWork W2004516134 @default.
• W3023367083 hasRelatedWork W2013177684 @default.
• W3023367083 hasRelatedWork W2063860558 @default.
• W3023367083 hasRelatedWork W2131495810 @default.
• W3023367083 hasRelatedWork W2132880199 @default.
• W3023367083 hasRelatedWork W2376386228 @default.
• W3023367083 hasRelatedWork W2732573142 @default.
• W3023367083 hasRelatedWork W2885562532 @default.
• W3023367083 hasVolume "47" @default.
• W3023367083 isParatext "false" @default.
• W3023367083 isRetracted "false" @default.
• W3023367083 magId "3023367083" @default.
• W3023367083 workType "article" @default.